Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

VANCOUVER, July 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can potentially reduce the number of stents used in more complex cases, simplifying procedures and reducing costs. It affords a more efficient treatment option for the estimated 8 to 10 percent(1) of patients with long lesions. Boston Scientific plans to launch the product in the U.S. next month. It received CE Mark approval in 2007.

"The TAXUS Liberte Long Stent offers physicians and patients distinct advantages compared to using two overlapping drug-eluting stents," said Mark Turco, M.D., FACC, FSCAI, Director of the Center for Cardiac Vascular Research at Washington Adventist Hospital, Takoma Park, Maryland. "In the ATLAS Long Lesion Trial, the 38 mm TAXUS Liberte Stent significantly reduced myocardial infarction when compared to the TAXUS(R) Express(R) Stent, making the TAXUS Liberte Long Stent an attractive option for interventional cardiologists faced with long, challenging lesions."

The TAXUS ATLAS Long Lesion Trial reported a significant 79 percent reduction in the rate of nine-month myocardial infarction for the TAXUS Liberte Long Stent as compared to the TAXUS Express Stent control (1.3% vs. 6.3%, p=0.026). At two years, the composite measure of cardiac death or myocardial infarction showed a significant 63 percent reduction for the TAXUS Liberte Long Stent compared to
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... ... its 2015 growth plan and as a follow up to the recently announced expansion of ... pleased to announce that it has begun construction on a new Microbiological Laboratory. The new ... dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw materials. ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance in ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 2015: ... , Turkey and the United Kingdom ... excluding U.S. HPV sales, on demand across all customer classes. The top seven ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... , ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits and Risks ... , ... 2009 -- The Drug Information Association (DIA) and the US Food and Drug ...
... ... Products announced a financial support partnership with several key vendors to ... collective effort with a dedicated "Pink" section on their website, ... will be available. Spectrum will also donate $1 per order ...
... Inc. (OTC Bulletin Board: BTEL) announced results for the fiscal ... or $0.33 per diluted share, on revenues of $12,640,000. ... diluted share on revenues of $11,495,000 in fiscal year 2008. ... of $174,000 or $0.06 per diluted share, on revenues of ...
Cached Biology Technology:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 2Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 3Biotel Announces Fourth Quarter and Year End Results 2
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... start-ups Straw Fuels and AdFerTech have won prizes ... supported by the EU,s main climate innovation initiative, ... the Climate-KIC Early Stage Entrepreneurs Prize, which will ... of Climate-KIC,s pan-European start-up Acceleration Programme. Straw Fuels, ...
... Colo., USA GSA Bulletin postings ... as seen in the Pyrenees; facies architecture in ... Permian Maroon Formation; preglacial fluvial gorges and valleys; ... Africa; Ediacaran fossils from Mistaken Point, Newfoundland; geologic ...
... Increasing block-rate water budgets are an innovative type of ... sizes are based on household characteristics, environmental conditions, and ... what constitutes "efficient" water use given those characteristics and ... relatively low for the most essential uses of water ...
Cached Biology News:Liquor converter, BBQ logs win €20K prizes at UK innovation showcase 2Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 2Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 3Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 4Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 5Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 6Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 7Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 8Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 9Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 10An innovative approach to promote water use efficiency 2An innovative approach to promote water use efficiency 3
... Exiqon's miRCURY LNA technology enables sensitive and ... blotting. miRCURY LNA Detection probes have high ... and sensitive detection of miRNAs. Due to ... LNA probes less than 1/10 the amount ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length Vitronectin protein (Mouse). Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... [PRMT5-21] to PRMT5 Arginine methylation is ... only recently been linked to protein activity. ... have been identified in mammalian cells. These ... regulatory functions by methylation of key proteins ...
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
Biology Products: